TB Archives – Page 25 of 48 – Treatment Action Group

Research Priorities for Pediatric Tuberculosis

September 19, 2018
Chad Cipiti

This document (not a TAG publication) presents an overview of paediatric TB research efforts already underway and their limitations; and highlights priorities for future research initiatives in epidemiology, basic science, prevention, diagnosis, treatment and operational research.

The TB CAB and TAG Welcome WHO Recommendation of Injectable-Free Regimens for the Treatment of RR/MDR-TB

August 17, 2018
Chad Cipiti

The Global Tuberculosis Community Advisory Board (TB CAB) and Treatment Action Group (TAG) welcome the new World Health Organization (WHO) recommendation of injectable-free regimens for the treatment of rifampicin- and multidrug-resistant tuberculosis (RR/MDR-TB).

Implementing an Injectable-Free Regimen for Drug-Resistant Tuberculosis

August 16, 2018
Chad Cipiti

Treatment Action Group (TAG), the Global Tuberculosis Community Advisory Board (CAB), the DR-TB Scale-Up Treatment Action Team (DR-TB STAT), and TB Proof hosted a webinar on Thursday, August 16, 2018 to discuss the evidence for and importance of using bedaquiline-based,…

U.S. TB and Access to Medicines Stakeholder Letter to U.S. Amb. Nikki Haley on HLM Declaration Negotiations

August 8, 2018
Chad Cipiti

In response to the reopening of negotiations on the TB High-Level Meeting (HLM) political declaration, a coalition of U.S.-based civil society stakeholders have submitted a letter to U.S. Ambassador to the UN, Nikki Haley, urging a diplomatic solution to the contentious provisions on access to medicines.

Activists Call on Countries and Donors to Immediately Scale Up Use of Life-Saving TB LAM Test

July 22, 2018
Chad Cipiti

At the TB 2018 pre-conference held on Sunday 22 July 2018, before the International AIDS Conference in Amsterdam, activists from around the globe called on their countries, development partners, and donors, to end the unacceptable death rates caused by TB in people living with HIV by immediately scaling up the use of TB LAM testing.

Strengthening TB Research in NIAID’s Tuberculosis Strategic Plan

July 17, 2018
Chad Cipiti

Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

July 16, 2018
Chad Cipiti

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

TB Research Briefing for UN Mission: Vital Role of Research for TB Elimination

July 5, 2018
Chad Cipiti

TB Research Briefing for UN Missions: THE VITAL ROLE OF RESEARCH FOR TB ELIMINATION This briefing in New York City on June 4, 2018 provided an opportunity for discussion on the importance of investing in the full spectrum of TB…

TAG Welcomes Price Reductions for TB Medicines

June 19, 2018
Chad Cipiti

Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required.

TAGline Spring 2018

April 10, 2018
Chad Cipiti

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.